Merck Prevails Over Johns Hopkins in Patent Battle Over Colorectal Cancer Drug

In a significant development within the pharmaceutical and academic sectors, Merck & Co. Inc.’s subsidiary, Merck Sharp & Dohme LLC, has successfully challenged a patent held by Johns Hopkins University regarding a colorectal cancer treatment. This verdict was rendered by a panel at the Patent Trial and Appeal Board (PTAB), which ruled to invalidate the claims associated with the university-owned patent. The dispute arises from a research collaboration between Merck and Johns Hopkins, with the resolution possibly reshaping aspects of future agreements between major pharmaceutical companies and academic institutions. For more details, refer to the article on Law360.